These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 20850381)

  • 21. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxorubicin-induced myocardial injury.
    Fujisaki G; Inokuchi C; Murashige N
    N Engl J Med; 2004 Oct; 351(18):1908-9; author reply 1908-9. PubMed ID: 15509827
    [No Abstract]   [Full Text] [Related]  

  • 23. Dexrazoxane Treatments Limits Subclinical Cardiac Dysfunction in Childhood Acute Lymphoblastic Leukemia Survivors Exposed to Doxorubicin Treatments.
    Lapointe MO; Caru M; Curnier D; Raboisson MJ; Andelfinger G; Krajinovic M; Laverdière C; Sinnett D; Périé D
    J Pediatr Hematol Oncol; 2023 Mar; 45(2):70-77. PubMed ID: 36161876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
    Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
    Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
    Lipshultz SE; Lipsitz SR; Mone SM; Goorin AM; Sallan SE; Sanders SP; Orav EJ; Gelber RD; Colan SD
    N Engl J Med; 1995 Jun; 332(26):1738-43. PubMed ID: 7760889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
    Krajinovic M; Elbared J; Drouin S; Bertout L; Rezgui A; Ansari M; Raboisson MJ; Lipshultz SE; Silverman LB; Sallan SE; Neuberg DS; Kutok JL; Laverdière C; Sinnett D; Andelfinger G
    Pharmacogenomics J; 2016 Nov; 16(6):530-535. PubMed ID: 26345518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dexrazoxane as a cardioprotectant in children receiving anthracyclines.
    Sepe DM; Ginsberg JP; Balis FM
    Oncologist; 2010; 15(11):1220-6. PubMed ID: 21051660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.
    Hellmann K
    Support Care Cancer; 1996 Jul; 4(4):305-7. PubMed ID: 8829310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
    Barry EV; Vrooman LM; Dahlberg SE; Neuberg DS; Asselin BL; Athale UH; Clavell LA; Larsen EC; Moghrabi A; Samson Y; Schorin MA; Cohen HJ; Lipshultz SE; Sallan SE; Silverman LB
    J Clin Oncol; 2008 Mar; 26(7):1106-11. PubMed ID: 18309945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.
    Yang W; Cai J; Shen S; Gao J; Yu J; Hu S; Jiang H; Fang Y; Liang C; Ju X; Wu X; Zhai X; Tian X; Wang N; Liu A; Jiang H; Jin R; Sun L; Yang M; Leung AWK; Pan K; Zhang Y; Chen J; Zhu Y; Zhang H; Li C; Yang JJ; Cheng C; Li CK; Tang J; Zhu X; Pui CH
    Lancet Oncol; 2021 Sep; 22(9):1322-1332. PubMed ID: 34329606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children.
    Lo AC; Liu A; Liu Q; Yasui Y; Castellino SM; Kelly KM; Hererra AF; Friedberg JW; Friedman DL; Schwartz CL; Pei Q; Kessel S; Bergeron-Gravel S; Dama H; Roberts K; Constine LS; Hodgson DC
    JAMA Netw Open; 2024 Jan; 7(1):e2351062. PubMed ID: 38241048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis.
    Cheung YT; Sabin ND; Reddick WE; Bhojwani D; Liu W; Brinkman TM; Glass JO; Hwang SN; Srivastava D; Pui CH; Robison LL; Hudson MM; Krull KR
    Lancet Haematol; 2016 Oct; 3(10):e456-e466. PubMed ID: 27658980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.
    Chow EJ; Aplenc R; Vrooman LM; Doody DR; Huang YV; Aggarwal S; Armenian SH; Baker KS; Bhatia S; Constine LS; Freyer DR; Kopp LM; Leisenring WM; Asselin BL; Schwartz CL; Lipshultz SE
    Cancer; 2022 Feb; 128(4):788-796. PubMed ID: 34644414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography.
    Paiva MG; Petrilli AS; Moisés VA; Macedo CR; Tanaka C; Campos O
    Pediatr Blood Cancer; 2005 Dec; 45(7):902-8. PubMed ID: 16035077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.
    Lipshultz SE; Lipsitz SR; Kutok JL; Miller TL; Colan SD; Neuberg DS; Stevenson KE; Fleming MD; Sallan SE; Franco VI; Henkel JM; Asselin BL; Athale UH; Clavell LA; Michon B; Laverdiere C; Larsen E; Kelly KM; Silverman LB
    Cancer; 2013 Oct; 119(19):3555-62. PubMed ID: 23861158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
    Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.
    Schwartz CL; Wexler LH; Krailo MD; Teot LA; Devidas M; Steinherz LJ; Goorin AM; Gebhardt MC; Healey JH; Sato JK; Meyers PA; Grier HE; Bernstein ML; Lipshultz SE
    Pediatr Blood Cancer; 2016 Jan; 63(1):54-61. PubMed ID: 26398490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography.
    Hauser M; Gibson BS; Wilson N
    Eur J Pediatr; 2001 Oct; 160(10):607-10. PubMed ID: 11686505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
    Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
    J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
    Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
    Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.